IMV Inc. appointed Julia Gregory as a board member.
Gregory recently served as CEO and director of ContraFect Corp., a public biotechnology company developing anti-infectives.
Nova Scotia-based IMV is a clinical-stage company that, with its subsidiaries, develops products based on its platform and products with a primary focus on T-cell activating therapies for cancer.
